Home LiteratureArticle Details
PMID: 18560578 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.

PloS one ·Vol. 3 ·No. 6 ·2008-06-18 ·Pages e2425

Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H, O'Briant KC, Drescher CW, Schummer M, McIntosh MW, Knudsen BS, Hanash SM

Abstract

Elucidation of the repertoire of secreted and cell surface proteins of tumor cells is relevant to molecular diagnostics, tumor imaging and targeted therapies. We have characterized the cell surface proteome and the proteins released into the extra-cellular milieu of three ovarian cancer cell lines, CaOV3, OVCAR3 and ES2 and of ovarian tumor cells enriched from ascites fluid. To differentiate proteins released into the media from protein constituents of media utilized for culture, cells were grown in the presence of [(13)C]-labeled lysine. A biotinylation-based approach was used to capture cell surface associated proteins. Our general experimental strategy consisted of fractionation of proteins from individual compartments followed by proteolytic digestion and LC-MS/MS analysis. In total, some 6,400 proteins were identified with high confidence across all specimens and fractions. Protein profiles of the cell lines had substantial similarity to the profiles of human ovarian cancer cells from ascites fluid and included protein markers known to be associated with ovarian cancer. Proteomic analysis indicated extensive shedding from extra-cellular domains of proteins expressed on the cell surface, and remarkably high secretion rates for some proteins (nanograms per million cells per hour). Cell surface and secreted proteins identified by in-depth proteomic profiling of ovarian cancer cells may provide new targets for diagnosis and therapy.

MeSH Terms
Cell Line, Tumor Chromatography, Liquid Extracellular Space/metabolism Female Humans Neoplasm Proteins/metabolism Ovarian Neoplasms/metabolism Proteomics Tandem Mass Spectrometry
Chemicals
Neoplasm Proteins
Authors & Affiliations
15 authors, click to expand affiliations / ORCID
Faça Vitor M
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Ventura Aviva P
Fitzgibbon Mathew P
Pereira-Faça Sandra R
Pitteri Sharon J
Green Ann E
Ireton Renee C
Zhang Qing
Wang Hong
O'Briant Kathy C
Drescher Charles W
Schummer Michèl
McIntosh Martin W
Knudsen Beatrice S
Hanash Samir M
References (39)
39 references, click to expand
  1. Current management strategies for ovarian cancer.
    Mayo Clin Proc. 2007 Jun;82(6):751-70 PMID: 17550756
  2. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1.
    Proteomics. 2005 Sep;5(14):3790-7 PMID: 16121334
  3. False discovery rates and related statistical concepts in mass spectrometry-based proteomics.
    J Proteome Res. 2008 Jan;7(1):47-50 PMID: 18067251
  4. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma.
    Proteomics. 2006 Nov;6(21):5880-90 PMID: 17022098
  5. Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments.
    J Proteome Res. 2006 Jan;5(1):112-21 PMID: 16396501
  6. Mining the plasma proteome for cancer biomarkers.
    Nature. 2008 Apr 3;452(7187):571-9 PMID: 18385731
  7. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.
    Cancer Res. 1983 Nov;43(11):5379-89 PMID: 6604576
  8. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.
    Gynecol Oncol. 1994 Apr;53(1):70-7 PMID: 7909787
  9. Plasma proteomic pattern as biomarkers for ovarian cancer.
    Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:139-46 PMID: 16515582
  10. Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer.
    Clin Cancer Res. 2007 Jul 1;13(13):3848-54 PMID: 17606716
  11. Calsyntenin-1, a proteolytically processed postsynaptic membrane protein with a cytoplasmic calcium-binding domain.
    Mol Cell Neurosci. 2001 Jan;17(1):151-66 PMID: 11161476
  12. Comparative proteome analysis of human epithelial ovarian cancer.
    Proteome Sci. 2007 Sep 24;5:16 PMID: 17892554
  13. The PeptideAtlas project.
    Nucleic Acids Res. 2006 Jan 1;34(Database issue):D655-8 PMID: 16381952
  14. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes.
    J Proteome Res. 2007 Sep;6(9):3558-65 PMID: 17696519
  15. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.
    Anal Chem. 2002 Oct 15;74(20):5383-92 PMID: 12403597
  16. Locating proteins in the cell using TargetP, SignalP and related tools.
    Nat Protoc. 2007;2(4):953-71 PMID: 17446895
  17. Soluble cadherins as cancer biomarkers.
    Clin Exp Metastasis. 2007;24(8):685-97 PMID: 17952616
  18. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC).
    Nat Protoc. 2006;1(6):2650-60 PMID: 17406521
  19. Quantitative proteomics analysis of the secretory pathway.
    Cell. 2006 Dec 15;127(6):1265-81 PMID: 17174899
  20. A gene atlas of the mouse and human protein-encoding transcriptomes.
    Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 PMID: 15075390
  21. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers.
    J Proteome Res. 2008 Jan;7(1):339-51 PMID: 18076136
  22. Innovative proteomic approaches for cancer biomarker discovery.
    Biotechniques. 2007 Sep;43(3):279, 281-3, 285 PMID: 17907570
  23. Distribution of 15 human kallikreins in tissues and biological fluids.
    Clin Chem. 2007 Aug;53(8):1423-32 PMID: 17573418
  24. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function.
    J Biol Chem. 2003 Feb 28;278(9):7607-16 PMID: 12493773
  25. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Anticancer Res. 2007 Jul-Aug;27(4C):2753-8 PMID: 17695443
  26. Large-scale proteomics analysis of human ovarian cancer for biomarkers.
    J Proteome Res. 2007 Apr;6(4):1440-50 PMID: 17315909
  27. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells.
    Mol Cancer Res. 2007 Dec;5(12):1246-53 PMID: 18171982
  28. Advantages of combined transmembrane topology and signal peptide prediction--the Phobius web server.
    Nucleic Acids Res. 2007 Jul;35(Web Server issue):W429-32 PMID: 17483518
  29. A model for random sampling and estimation of relative protein abundance in shotgun proteomics.
    Anal Chem. 2004 Jul 15;76(14):4193-201 PMID: 15253663
  30. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells.
    Cancer Res. 2007 Mar 1;67(5):2030-9 PMID: 17332331
  31. A statistical model for identifying proteins by tandem mass spectrometry.
    Anal Chem. 2003 Sep 1;75(17):4646-58 PMID: 14632076
  32. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations.
    Lancet Oncol. 2007 Sep;8(9):813-21 PMID: 17765190
  33. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.
    Cancer Res. 2002 Aug 15;62(16):4722-9 PMID: 12183431
  34. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
    Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 PMID: 10500211
  35. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands.
    Nature. 2007 May 24;447(7143):482-6 PMID: 17495932
  36. Comparative proteomics of ovarian epithelial tumors.
    J Proteome Res. 2006 May;5(5):1082-90 PMID: 16674097
  37. Cancer statistics, 2007.
    CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 PMID: 17237035
  38. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Cancer Res. 1991 Oct 1;51(19):5181-7 PMID: 1717140
  39. Ovarian cancer metastasis: integrating insights from disparate model organisms.
    Nat Rev Cancer. 2005 May;5(5):355-66 PMID: 15864277
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
Published
2008-06-18
Epub
2008-00-18
Pages
e2425
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC2409963
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com